

ABSTRACT

Summary

The invention relates to the use of a LAPT4B-interacting molecule for the preparation of a pharmaceutical composition for the treatment of a neurodegenerative disease. Hereby the LAPT4B-interacting molecule is preferably an inhibitor of LAPT4B and particularly it has the capacity to modulate the activity of gamma-secretase and/or beta-secretase. Furthermore the invention concerns a process for identifying a gamma-secretase and/or a beta-secretase modulator, comprising the following steps: a) identifying of a LAPT4B-interacting molecule by determining whether a given test compound is a LAPT4B-interacting molecule, and b) determining whether the LAPT4B-interacting molecule of step a) is capable of modulating gamma-secretase and/or beta-secretase activity.